BioStem Technologies, Inc. Announces Completion of 503b Pharmaceutical and Stem Cell Research Laboratory
March 24 2017 - 2:55PM
Marketwired
OAKLAND PARK, FL-(Marketwired - Mar 24, 2017) - BioStem
Technologies, Inc. (OTC PINK: BSEM) ("BSEM" or "the company"), an
emerging International BioTech company, celebrated the opening of
its new laboratory and corporate offices with a ribbon cutting
ceremony hosted by the BioStem Technologies executive team. BSEM's
Founder and CEO, Henry Van Vurst, commented, "With the recent
regulation changes we amended our original facility design to
comply with FDA 503b regulations, which caused an extension to our
timeline, but I couldn't be prouder of this new state-of-the-art
facility. Cutting the ribbon with Mayor Lamar Fisher (City of
Pompano Beach) was a very proud moment for the entire BSEM team,
and it is a testament to how far we have come since the Company's
inception in 2014."
The facility is a showcase of quality that will enable BSEM to
leverage its vertical integration strategy in the Health, Wellness
and Biotechnology sectors. The lab will serve as the Quality,
R&D, and Pharmaceutical Manufacturing Laboratory, not only for
the Company's in-house operations, but also for its contract
formulation and contract manufacturing services. The Company is in
the process of finalizing its certifications for the ISO 8, 7, and
5 suites, as well as validation of the cGMP and cGLP areas.
Corporate operations are expected to move to the new facility in Q2
2017, while the operations of Qualified Pharma Ingredients, one of
the company's subsidiaries, will remain at its current location in
Oakland Park, Florida.
About BioStem Technologies, Inc. (OTC PINK: BSEM): BioStem
Technologies, Inc. (OTC PINK: BSEM) is in the business of
regenerative medicine and antiaging strategies throughout the
United States, Europe, and Mexico. The Company's mission is to
conquer the effects of biological aging (and related acute
disease), and its strategy is to discover, develop, produce, and
deliver the most effective stem cell and wellness products in the
world. The Company is comprised of a diverse group of scientists,
physicians, and industry visionaries who are creating innovative
products for helping customers live their best, feel their best,
and be their best. The company operates six strategic business
units - BioStem Cell Therapy, BioStem Wellness, BioStem
Pharmaceuticals, Qualified Pharma Ingredients, BioBlue, and BioStem
International - providing a diversified line of products and
services that include: clinical stem cell therapy, stem cell
R&D, state-of-the-art laboratory services, pharmaceuticals,
nutraceuticals, cosmeceuticals, API repackaging, and medical
tourism.
Forward-Looking Statements: Except for statements of historical
fact, the matters discussed in this press release are forward
looking and made pursuant to the Safe Harbor provisions of the
Private Securities Litigation Reform Act of 1995. "Forward-looking
statements" describe future expectations, plans, results, or
strategies and are generally preceded by words such as "future,"
"plan" or "planned," "expects," believe" or "projected." These
forward-looking statements reflect numerous assumptions and involve
a variety of risks and uncertainties, many of which are beyond the
company's control that may cause actual results to differ
materially from stated expectations. These risk factors include,
among others, limited operating history, difficulty in developing,
exploiting and protecting proprietary technologies, intense
competition and additional risks factors as discussed in reports
filed by the company with OTC Markets.
BioStem Technologies, Inc.
Phone: 954-380-8342
Website: http://www.biostemtech.com
Email: info@biostemtech.com
Twitter: @Biostemtech
Facebook: BioStem Technologies
Investor Relations: Andrew Van Vurst
info@biostemtech.com
954.380.8342
BioStem Technologies (PK) (USOTC:BSEM)
Historical Stock Chart
From Dec 2024 to Jan 2025
BioStem Technologies (PK) (USOTC:BSEM)
Historical Stock Chart
From Jan 2024 to Jan 2025